Feminai Ltd.

Feminai, based in Israel, specializes in innovative breast cancer diagnostics, providing a smart, wearable patch and app for women to conduct self-testing, enhancing accessibility and early detection. Founded in 2023 by co-founders Karny Ilan, Shani Klein Antman, and Gal Yanuka in Tel Aviv, Israel, Feminai develops advanced diagnostic solutions for breast cancer. In January 2026, Feminai raised USD 6 million in seed funding led by investor Vertex Ventures Israel, with participation from other investors ICI Fund (Innovation Community Intelligence), Fusion, Arben Ventures, and Cactus Capital also participated in the round. Feminai specializes in innovative breast cancer diagnostics through its flagship product, a smart, wearable, disposable patch designed for self-testing.

This patch is paired with a user-friendly app that enables women to identify breast lesion abnormalities in a non-intrusive manner, promoting accurate and timely screenings. The core service aims to empower women by facilitating independent health monitoring from the comfort of their own homes, which addresses critical gaps in accessibility and affordability in breast cancer diagnostics. Feminai’s customer base primarily consists of women seeking proactive health management solutions, though it also targets healthcare providers and institutions that prioritize early detection. The company aims to penetrate various geographical markets, focusing on urban and suburban areas where access to traditional screening methods may be limited.

Feminai generates revenue through direct-to-consumer sales of its self-breast examination patch and associated app. The typical transaction structure involves customers purchasing the patch directly, supported by a subscription model for ongoing app updates and features. This pricing model allows users to have continuous access to the latest diagnostic tools and features, enhancing their self-testing experience. Feminai's primary product, the self-breast exam patch, serves as the cornerstone of its revenue strategy, targeting both individual consumers and partnerships with healthcare facilities that advocate for women's health initiatives.

By establishing these relationships, Feminai aims to enhance its market reach and impact the breast cancer screening landscape significantly. The company will use the January 2026 funding to strengthen its team, accelerate regulatory approval, and prepare for market entry.